Claims for Patent: 6,068,976

Summary for Patent: 6,068,976

Title:	Modulators of ob gene and screening methods therefor
Abstract:	This invention relates to the isolation and cloning of the promoter and other control regions of a human ob gene. It provides a method for identifying and screening for agents useful for the treatment of diseases and pathological conditions affected by the level of expression of an ob gene. These agents interact directly or indirectly with the promoter or other control regions of the ob gene. A PPAR.gamma. agonist, BRL49653, has been identified to be useful in treating anorexia, cachexia, and other diseases characterized by insufficient food intake or body weight loss. Modulators of ob gene expression may be used to treat other diseases such as obesity, diabetes, hypertension, cardiovascular diseases and infertility.
Inventor(s):	Briggs; Michael R. (Downingtown, PA), Auwerx; Johan (Millionfosse, FR), de Vos; Piet (Zingem, BE), Staels; Bart (Kraainem, BE), Croston; Glenn E. (San Diego, CA), Miller; Stephen G. (San Diego, CA)
Assignee:	Ligand Pharmaceuticals Incorporated (San Diego, CA)
Application Number:	08/618,100
Patent Claims:	1. An isolated, purified, enriched or recombinant nucleic acid comprising a control region of the human ob gene wherein said control region is selected from the group consisting of 5' non-coding sequence of SEQ. ID. NO. 1, intron one of SEQ. ID. NO. 3, and SEQ. ID. NO. 4. 2. The nucleic acid of claim 1, wherein said control region comprises the sequence 5' to exon 1 of said human ob gene cloned in a P1 plasmid or a portion thereof, wherein said P1 plasmid is selected from the group consisting of P1 clone 5135, P1 clone 5136, and P1 clone 5137, all of which are deposited at American Type Culture Collection with accession numbers 69761, 69762, and 69763, respectively. 3. The nucleic acid of claim 1, wherein said control region comprises a positive transcription element capable of up regulating or a negative transcription element capable of down regulating the transcription of said human ob gene. 4. The nucleic acid of claim 3, wherein said negative transcription element comprises nucleotide -978 to -217, relative to the transcription initiation site, of said human ob gene or its complementary strand. 5. The nucleic acid of claim 3, wherein said negative transcription element comprises -1869 to -217, relative to the transcription site of said human ob gene or its complementary strand. 6. The nucleic acid of claim 1, wherein said control region is from the 5' upstream of the transcription initiation site of the human ob gene. 7. The nucleic acid of claim 1, wherein said control region is from a region between the transcription initiation site of the human ob gene and the HindIII site about 3 kb upstream of said transcription initiation site. 8. The nucleic acid of claim 1, wherein said control region is from a region between Exon 1 and Exon 2 of the human ob gene. 9. The nucleic acid of claim 1, wherein said control region comprises a transcription regulation element selected from the group consisting of PPRE, RXRE, GRE, insulin response element, SP1 binding site, Oct-1 binding site, serum response element, cAMP response element, AP-1 binding site, AP-2 binding site, NF.kappa.B site and C/EBP binding site. 10. The nucleic acid of claim 1, wherein said control region comprises a C/EBP binding site or a Sp1 binding site from SEQ. ID NO. 1. 11. Isolated, purified, enriched or recombinant nucleic acid comprising a promoter of a human ob gene capable of initiating the transcription of said human ob gene. 12. The nucleic acid of claim 11, wherein said promoter comprises nucleotide -217 to -1, relative to the transcription initiation site, of said human ob gene or its complementary strand. 13. The nucleic acid of claim 11, wherein said promoter comprises nucleotide -2921 to -1, relative to the transcription initiation site, of said human ob gene or its complementary strand. 14. The nucleic acid of claim 11, wherein said promoter comprises at least 60 contiguous nucleotides from nucleotide -217 to -1, relative to the transcription initiation site, of said human ob gene or its complementary strand. 15. A recombinant nucleic acid comprising a control region of a human ob gene tanscriptionally linked to a reporter sequence for the effective initiation or regulation of transcription of said reporter sequence, said control region comprising at least 12 contiguous nucleotides from a 5' non-coding sequence of said human ob gene selected from the group consisting of SEQ. ID. NO. 1, intron one of SEQ. ID. NO. 3, and SEQ. ID. NO. 4. 16. A vector comprising the recombinant nucleic acid of claim 15, wherein said control region and reporter sequence are inserted therein. 17. A vector comprising the recombinant nucleic acid of claim 15, wherein said control region comprises a positive transcription element or a negative transcription element of said human ob gene. 18. The vector of claim 17, wherein said negative transcription element comprises nucleotide -978 to -217, relative to the transcription initiation site, of said human ob gene or its complementary strand. 19. The vector of claim 17, wherein said negative transcription element comprises nucleotide -1869 to -217, relative to the transcription initiation site, of said human ob gene or its complementary strand. 20. The vector of claim 17 selected from the group consisting of pGL3-OB.DELTA.12 and pGL3-OB.DELTA.5. 21. An isolated, purified, enriched or recombinant nucleic acid comprising a control region of the human ob gene wherein said control region is selected from the group consisting of SEQ. ID. NO. 1, inton one of SEQ. ID. NO. 3, and SEQ. ID. NO. 4. 22. An isolated, purified, enriched or recombinant nucleic acid consisting of a fragment of at least 12 contiguous nucleotides of SEQ. ID. NO. 1, or intron one of SEQ. ID. NO. 3, or SEQ. ID. NO. 4. 23. An isolated, purified, enriched or recombinant nucleic acid of claim 22, consisting of a fragment of at least 30 contiguous nucleotides of SEQ ID. NO. 1, intron one of SEQ ID. NO. 3, or SEQ ID. NO. 4. 24. A vector comprising a recombinant nucleic acid comprising a promoter of a human ob gene and a reporter sequence; wherein said promoter is tanscriptionally linked to said reporter sequence so as to effectively initiate the transcription of said reporter sequence. 25. The vector of claim 24, wherein said promoter comprises nucleotide -2921 to -1 , relative to the transcription initiation site, of said human ob gene or its complementary strand. 26. The vector of claim 24, wherein said promoter comprises nucleotide -217 to -1, relative to the transcription initiation site, of said human ob gene or its complementary strand. 27. The vector of claim 24 selected from the group consisting of pGL3B-OB1, pGL3B-OB2, pGL3B-OB3 and pGL3B-OB4. 28. A method for screening for an agent modulating the expression of a human ob gene, comprising the steps of: providing a cell containing a control region of said human ob gene and a reporter sequence transcriptionally linked to said control region wherein said control region is effective to initiate, terminate or regulate the transcription of said reporter sequence; contacting a agent with said cell; and comparing the level of transcription of said reporter sequence with the level in the absence of said agent; wherein a measurable difference in the level of transcription of said reporter sequence is an indication that said agent is useful for modulating the expression of said human ob gene. 29. The method of claim 28, wherein said control region and reporter sequence are inserted in a vector. 30. The method of claim 28, wherein said cell further comprises a transcriptional protein. 31. The method of claim 30, wherein said transcriptional protein is an intracellular receptor. 32. The method of claim 31, wherein said intracellular receptor is PPAR.gamma. or PPAR.alpha.. 33. The method of claim 30, wherein said transcriptional protein is expressed from a recombinant nucleic acid in said cell. 34. The method of claim 30, wherein said transcriptional protein binds to a C/EBP site in SEQ. ID NO.1. 35. The method of claim 28, wherein said control region and reporter sequence are inside a preadipocyte cell. 36. The method of claim 28, wherein said control region and reporter sequence are inside an adipocyte cell. 37. The method of claim 28, wherein said control region and reporter sequence are inside a primary adipocyte cell. 38. The method of claim 28, wherein said control region and reporter sequence are inside a cell selected from the group consisting of COS, 3T3-L1, rat primary adipocyte, human primary adipocyte, mouse primary adipocyte and immortalized adipocyte cell. 39. The method of claim 28, wherein said agent is selected from the group consisting of glucocorticoids; thyroid hormones; thyromimetics; fibrates, free fatty acids and other agonists of PPAR including Di-(2-ethylhexyl)-phthalate, plasticizers and herbicides including 2,4,5-trichlorophenoxyacetic acid and leukotriene antagonists; antagonists of PPAR and PPAR subtype selective compounds; RAR selective agonists and antagonists including subtype selective compounds; RXR selective agonists and antagonists including subtype selective compounds; estrogens and other agonists and antagonists of ER; androgens and other agonists and antagonists of AR; progestins and other agonists and antagonists of PR; non-steroid progestins; mineralocorticoids and other agonists and antagonists of MR; insulin; glucose; glucagon; free fatty acids; amino acids; sugars and other secretagogues including biguanides; antidiabetics including metformin and phenformin; pyroglyrides; linoglyrides and benzothenediones; non-steroidal anti-inflammatory drugs; prostacyclins; dihydroepiandosterone and stimulators, precursors and derivatives thereof including Dioscorea and aloe vera, and extracts and compounds derived therefrom; tumor necrosis factors; cytokines and related signaling molecules; growth factors; fetuin; Amylin agonists and antagonists; prolactin; niacin; Acepimox and other nicotinic acid derivatives; triacsins; amphetamines and derivatives including fenfluramine and dexfenfluramine; endorphin antagonists; somatostatin; cholecystokinin; bombesin; gastrin; oral anti-diabetic agents; corticotropin releasing hormone; thiazolidinedione compounds; adrenocorticotropic hormones; melanocyte stimulating hormone; gastric inhibitory peptide; growth hormone agonists and antagonists; .beta.-adrenergic agonists and antagonists including phenoxybenzamide; fluloxetine; neuropeptide Y and agents modulating neuropeptide Y activity or expression. 40. The method of claim 28 used to screen for an agent increasing the transcription of said human ob gene, wherein said agent is selected from the group consisting of PPAR.gamma. antagonist, C/EBP protein agonist, PPAR.alpha. agonist, glucocorticoid, insulin derivative, insulin secretagogue, insulin sensitizer and insulin mimetic. 41. The method of claim 28 used to screen for an agent decreasing the transcription of said human ob gene, wherein said potential agent is selected from the group consisting of PPAR.gamma. agonist, C/EBP protein antagonist, PPAR.alpha. antagonist, glucocorticoid antagonist, and insulin antagonist. 42. The method of claim 41, wherein said PPAR.gamma. agonist is a thiazolidinedione compound.

Details for Patent 6,068,976

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2015-03-20
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2015-03-20
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2015-03-20